CompareRetinAIvsSully.ai

RetinAI is an AI ophthalmology platform for eye care clinics and research programs, combining ophthalmic data management with analysis across screening workflows.

1. Clinical role: It supports retinal screening and care routing rather than replacing ophthalmologists, while specialist follow-up remains essential for every positive screen surfaced through the workflow.
2. Best-fit environment: Clinics and research programs gain value when ophthalmic data management and AI analysis align with established imaging workflows.
3. Implementation checks: Buyers should confirm regulatory clearance, camera and imaging hardware compatibility, downstream referral integration, and program reporting before launching diabetic eye screening across primary care sites.
4. Commercial model: Pricing is sales-led and scoped per buyer rather than publicly posted, so value depends on imaging data workflow.

A focused pilot around one workflow is usually the clearest way to assess fit before wider adoption.

Sully.ai is an AI medical scribe and clinical assistant for clinics and physician practices, supporting ambient capture, structured note drafting, and documentation workflows.

1. Clinical role: It supports documentation rather than autonomous clinical decision-making, so clinician review of every drafted note remains essential before sign-off.
2. Best-fit environment: Clinics and physician practices may benefit most when specialty requirements and EHR workflows align with the product’s documentation approach.
3. Implementation checks: Buyers should assess specialty fit, EHR integration depth, documentation accuracy, clinician training, and rollout requirements before deployment.
4. Commercial model: Pricing is sales-led and scoped per buyer rather than publicly posted, making implementation scope an important purchasing consideration.

Sully.ai is best evaluated through a focused workflow pilot that tests documentation fit, clinician review, and readiness before scaling across teams.